AI-ECG Screening for Early Heart Failure Diagnosis (VISION-HF)
Validated AI-ECG Screening and Intervention for Optimizing Heart Failure Diagnosis
The goal of this parallel-group cluster randomized clinical trial is to evaluate whether opportunistic screening for left ventricular systolic dysfunction (LVSD), using an artificial intelligence algorithm applied to electrocardiograms (AI-ECG), increases the detection of previously unrecognized LVSD among adults aged ≥40 years receiving routine care in primary healthcare centers within the Brazilian Public Health System. LVSD is a key finding in the diagnosis of heart failure with reduced ejection fraction (HFrEF), a condition for which effective guideline-directed medical therapies are available but which remains underdiagnosed and undertreated.
The study will also evaluate the effects of AI-ECG screening on clinical management, healthcare utilization, implementation outcomes, and healthcare costs.
The main questions this study aims to answer are:
- Does adding AI-ECG screening to usual clinical assessment increase the proportion of patients with newly identified LVSD (left ventricular ejection fraction <50%) within six months compared with clinical assessment alone?
- Does AI-ECG screening improve the use of echocardiography, the recognition by primary care teams, and the initiation or optimization of guideline-directed medical therapy for HFrEF?
- How do LVSD detection rates differ between patients identified through AI-ECG screening alone and those identified through clinical suspicion alone?
- Is this screening strategy feasible, acceptable, and cost-effective when implemented in primary healthcare?
Primary healthcare centers will be randomized to either an intervention group, in which AI-ECG screening results will be provided alongside the standard ECG report, or a control group receiving usual care without AI-ECG results.
Participants will:
- Undergo a routine 12-lead electrocardiogram (ECG), as clinically indicated by their primary care physician.
- Be referred for echocardiography based on clinical suspicion of LVSD in both groups or, additionally, a positive AI-ECG screening result in the intervention group.
- Receive educational materials about HFrEF if newly diagnosed, while participating healthcare professionals will receive educational interventions on heart failure diagnosis and management.
- Complete questionnaires evaluating educational interventions, when applicable.
- Be followed for six months to assess newly identified LVSD, treatment initiation and optimization, healthcare utilization (including emergency visits and hospitalizations), mortality, implementation outcomes, and healthcare costs.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
-
Background: Cardiovascular diseases (CVD) are the main cause of death in Brazil. Among CVDs, heart failure with reduced ejection fraction (HFrEF) is the main cause of hospitalizations and costs for the public health system (Sistema Único de Saúde, SUS), which still tend to increase with population aging and greater survival rates from acute cardiovascular events. Guideline-directed medical therapy (GDMT) substantially reduces the risk of hospitalization and mortality among patients with HFrEF. Although several recommended therapies are available through the Brazilian Public Health System (SUS), their use remains suboptimal. Part of this is due to the lack of diagnosis, which requires an echocardiogram (ECHO) to diagnose left ventricular systolic dysfunction, an essential finding of HFrEF. ECHO is an expensive and complex exam, and therefore, with restricted access in primary health care (PHC), where patients can wait in lines more than 12 months to undergo an exam. Moreover, asymptomatic LVSD is also a condition that is considered preHF, which has specific GDMT to prevent it from evolving to clinical HFrEF.
The electrocardiogram (ECG) is a screening tool for the evaluation of heart disease and is widely available in primary health care (PHC) centers in Brazil. Although it provides valuable clinical information, conventional ECG interpretation cannot determine left ventricular ejection fraction (LVEF). Sangha et al. demonstrated that a convolutional neural network model can accurately identify left ventricular systolic dysfunction (LVSD) from ECGs. Although this model has been externally validated, including in the community-based ELSA-Brasil cohort, there is currently no evidence that implementing AI-ECG screening for LVSD at scale will change clinical practice.
-
Objectives: The overarching aim is to evaluate whether opportunistic screening for **LVSD** using an artificial intelligence algorithm applied to tele-electrocardiography (**AI-ECG for left ventricular systolic dysfunction [LVSD]**) increases the rate of LVSD diagnosis in routine clinical practice within Brazil's Unified Health System (SUS) primary care network. Our hypothesis is that informing the AI-ECG result to the primary care team will increase the rate of LVSD diagnosis in six months.
-
Study Design and Setting: VISION-HF is a multicenter, parallel-group, cluster-randomized clinical trial with a hybrid type 1 effectiveness-implementation design. The study will be conducted in primary healthcare centers (PHCs) in three or four Brazilian municipalities, each from a different Brazilian region. PHCs will be randomized to an intervention or control group.
-
Cluster selection: Primary healthcare centers (PHCs) will serve as the units of randomization. Participating PHCs will be selected by municipal health authorities and subsequently randomized to the intervention or control group, stratifed by municipality. In each municipality, participating centers will represent more than 30% of all PHCs.
-
Study Population: Individuals aged 40 years or older, with no previous diagnosis of left ventricular systolic dysfunction (LVSD), defined as left ventricular ejection fraction <50% who have been referred for an electrocardiogram (ECG) by their attending physician as part of routine clinical practice, will be invited to participate in the study. Patients who provide informed consent will be enrolled. Patients will be excluded if the ECG is uninterpretable.
-
Study Flow: After informed consent is obtained, participants' baseline information will be collected according to the routine ECG acquisition protocol. Clinical suspicion of HF will be defined by the attending physician, when requesting the ECG. Data will be entered into the software by the nurse technician performing the ECG as part of routine clinical practice, using a dedicated system developed by the HC-UFMG Telehealth Center (CTS-HC-UFMG), to which the data will be transmitted and stored. In the intervention group, an artificial intelligence algorithm will analyze routinely acquired ECGs to identify patients at increased risk of LVSD. AI-ECG screening results will be provided alongside the standard ECG report. Echocardiography will be offered to patients with a positive AI-ECG result or clinical suspicion of LVSD. In the control group, physicians will receive the standard ECG report without AI-ECG screening results. Echocardiography will be offered based on clinical suspicion alone. The study will provide access to echocardiography for participants meeting referral criteria in both groups, following the same procedures.
-
Sample Size Calculation: The sample size calculation assumes an intracluster correlation coefficient (ICC) of 0.01 and an average of 72 analyzable participants per primary healthcare center (PHC). The corresponding design effect is 1.71 [DE = 1 + (72 - 1) × 0.01]. The calculation is based on expected primary outcome rates of 1.8% in the control arm and 4.0% in the intervention arm, with a two-sided significance level of 5% and 90% statistical power. A total of 60 PHCs (30 per arm) are planned. To account for an anticipated 20% loss to follow-up, 90 participants will be recruited per PHC (5,400 overall), yielding an expected 72 analyzable participants per PHC (4,320 overall). The expected detection rates were based on data from the pilot study (10 PHCs in three municipalities, n=342), in which rates of 1.8% and 5.2% were observed in the control and intervention groups, respectively. A conservative estimate of 4.0% was used for the intervention group. The ICC assumption was informed by previous publications, including the EAGLE trial (Yao et al., Nature Medicine, 2021), and pilot study data. The power assessment for the key secondary outcome (diagnostic yield, defined as the number of newly identified LVSD cases divided by the number of echocardiograms performed in each arm) was based on pilot study data. The estimated statistical power was 100% across all scenarios.
-
Study Procedures and Follow-up: Participants will be followed for 6±1months. The primary outcome will be the proportion of participants with newly identified LVSD, defined as LVEF <50% on echocardiography. Echocardiographic images will be stored in a standardized format in a centralized database. All echocardiograms indicating LVSD (LVEF <50%) will undergo independent review by an expert at the central echocardiography reading center. A sample of echocardiograms without LVSD (LVEF ≥50%) will be randomly selected for central review to assess diagnostic consistency and quality. Local examiners and central reviewers will be blinded to treatment allocation and AI-ECG screening results. The echocardiography database will also be used to explore additional echocardiographic parameters of potential clinical and research interest. Additional assessments will include diagnostic yield, echocardiography utilization, documentation of newly identified LVSD in medical records, initiation or optimization of guideline-directed medical therapy, healthcare utilization, and mortality.
-
Statistical analysis: The participant will be the unit of analysis. Since randomization is performed at the public primary health care center (PHC) level, within-center correlation will be accounted for using generalized estimating equations (GEE), specifying the PHC as the clustering unit and an exchangeable working correlation structure. The primary analysis will follow the intention-to-treat principle, according to the randomized allocation of public primary health care centers (PHCs). The primary outcome, defined as a new diagnosis of left ventricular systolic dysfunction (LVSD; left ventricular ejection fraction [LVEF] <50%). Diagnostic yield will be considered a key secondary outcome and a power assessment has already been described under "sample size assumptions" section. All statistical analyses will be performed using R statistical software (R Foundation for Statistical Computing, Vienna, Austria), with a two-sided significance level of 5% (α = 0.05).
-
Implementation and Economic Evaluation
Implementation outcomes will be assessed using the RE-AIM framework, including reach, effectiveness, adoption, implementation, and maintenance. Capacity-building activities will provide educational resources for healthcare professionals and patients diagnosed with LVSD.
A qualitative component will include PHC physicians and participants to explore barriers and facilitators to AI-ECG implementation. Patients with positive AI-ECG screening results will also be invited to participate, including patients with and without echocardiographically confirmed LVSD. These discussions will explore patients' experiences, feelings, and perceptions regarding AI-ECG screening and its results. Transcripts will be coded, organized into thematic categories, and analyzed using qualitative content analysis. An economic evaluation will assess the cost-effectiveness of AI-ECG screening compared with usual care, incorporating study-specific diagnostic and resource utilization data, Brazilian healthcare costs, and, where feasible, longer-term economic modeling.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Luisa C Brant, MD, PhD
- Phone Number: 55 31 986530105
- Email: luisabrant@gmail.com
Study Contact Backup
- Name: Antonio Luiz P Ribeiro, MD, PhD
- Phone Number: 55 31 987090451
- Email: alpr1963br@gmail.com
Study Locations
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazil, 30130100
- Telehealth Center at Hospital das Clínicas
-
Contact:
- Luisa CC Brant, MD, PhD
- Phone Number: +5531986530105
- Email: luisabrant@gmail.com
-
Contact:
- Luana M Oliveira, BBA, PhD
- Phone Number: +5533988576938
- Email: luana.oliveira.16@hubrasil.gov.br
-
Principal Investigator:
- Luisa CC Brant, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Participating primary care centers were selected by the municipal health authorities. For participants, the inclusion criteria are: (1) having an ECG ordered by a primary care physician during routine care; (2) age ≥40 years; (3) no known left ventricular systolic dysfunction (left ventricular ejection fraction <50%); and (4) provision of written informed consent. Participants with uninterpretable ECGs will be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention
AI-ECG screening results for LVSD will be provided alongside the standard ECG report. AI-ECG results will be generated in real time through an application programming interface (API) connected to Yale University's Cardiovascular Data Science (CarDS) Lab (doi: 10.1161/CIRCULATIONAHA.122.062646). Physicians will be able to request an echocardiogram for patients with a positive AI-ECG screening result, as well as for patients with clinical suspicion of LVSD, defined prior to ECG acquisition. Given the limited availability of echocardiography services and prolonged waiting times in the participating municipalities, the study will provide echocardiograms for all eligible patients patients meeting the referral criteria in either study arm, following same referral procedures. |
AI-ECG results will be generated in real time through an application programming interface (API) connected to Yale University's Cardiovascular Data Science (CarDS) Lab. The AI-ECG algorithm was developed by the Yale CarDS Lab and previously validated for detecting LVSD (Sangha et al. Circulation. 2023;148:765-777. doi: 10.1161/CIRCULATIONAHA.122.062646). A positive AI-ECG screening result will be generated when the predicted probability of LVSD exceeds a predefined threshold of 0.10. This threshold was selected to achieve a sensitivity greater than 90% in the original internal validation study to detect left ventricular ejection fraction (LVEF)<40%. In the present study, it will be used to detect a LVEF<50%, as current guidelines uses this threshold for LVSD, which leads to clinical actions. |
|
No Intervention: Control
The standard ECG report will be provided without AI-ECG screening results. The AI-ECG algorithm will run in the background, but its results will not be disclosed to treating physicians or used to guide clinical decisions during the six-month follow-up period. Physicians will be able to request an echocardiogram for patients with clinical suspicion of LVSD, , defined prior to ECG acquisition. Given the limited availability of echocardiography services and prolonged waiting times in the participating municipalities, the study will provide echocardiograms for all eligible patients meeting the referral criteria, following the same referral procedures as in the intervention group. For ethical reasons, participants in the control group with a positive AI-ECG screening result who have not undergone echocardiography during the study will be offered an echocardiogram after completion of the six-month follow-up period. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of new diagnosis of left ventricular systolic dysfunction
Time Frame: 6 months
|
The primary outcome will be the proportion of participants with newly identified left ventricular systolic dysfunction (LVSD), defined as a left ventricular ejection fraction <50% on echocardiography, within six months of enrollment. The proportion will be calculated as the number of participants with newly identified LVSD divided by the total number of participants enrolled in each study arm. The primary analysis will compare the intervention and control groups according to the intention-to-treat principle, accounting for clustering at the primary healthcare center level. |
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Key secondary outcome: Diagnostic yield
Time Frame: 6 months
|
Diagnostic yield, calculated as the number of newly identified LVSD cases divided by the number of echocardiograms performed in each study arm. The power assessment was based on data from the pilot study (10 PHC in three municipalities, n=342). Expected event proportions were estimated by combining participants from both study arms and were 2.5% for those with clinical suspicion only, 29.2% for those with a positive AI-ECG and no clinical suspicion, and 26.7% for those with both a positive AI-ECG and clinical suspicion. These estimates correspond to overall expected diagnostic yields of 17.7% for the intervention strategy (clinical suspicion or positive AI-ECG) and 9.25% for clinical suspicion alone. Power was assessed under scenarios including 60 or 74 PHCs, 72 or 100 participants per PHC, and echocardiography completion rates of 80% or or 100%. The estimated statistical power was 100% across all scenarios. |
6 months
|
|
Number needed to diagnose a LVSD
Time Frame: 6 months
|
The number needed to diagnose will be calculated as the number of echocardiograms required to identify one case of LVSD. |
6 months
|
|
Incremental diagnostic yield
Time Frame: 6 months
|
The incremental diagnostic yield will be assessed as the difference between study arms in the number of newly identified LVSD cases per 100 participants. |
6 months
|
|
Agreement between clinical suspicion and AI-ECG positivity in identifying patients with LVSD
Time Frame: 6 months
|
Agreement between clinical suspicion and AI-ECG positivity will be assessed using Cohen's kappa coefficient, with 95% confidence intervals accounting for clustering at the primary healthcare center level. The overlap between the two screening strategies will also be described by calculating the proportions of participants identified exclusively through clinical suspicion, exclusively through AI-ECG positivity, or through both approaches. Among participants who undergo echocardiography, the proportion with confirmed LVSD (LVEF <50%) will be calculated for each subgroup to assess the diagnostic yield of the different screening strategies. |
6 months
|
|
Implementation outcome: Reach
Time Frame: 6 months
|
Reach will be assessed as the proportion of eligible individuals who agree to participate in the study. |
6 months
|
|
Implementation outcome: Effectiveness
Time Frame: 6 months
|
Effectiveness will be evaluated based on the primary study outcome, defined as the proportion of participants with newly identified left ventricular systolic dysfunction (LVSD) within six months. |
6 months
|
|
Implementation outcome: Adoption
Time Frame: 6 months
|
Adoption will be assessed as the proportion of physicians who request an echocardiogram after it is offered, stratified by the indication for echocardiography. |
6 months
|
|
Implementation outcome: Implementation
Time Frame: 6 months
|
Implementation will be evaluated through: (1) the proportion of indicated echocardiograms that are performed, (2) the proportion of participants with confirmed LVSD (left ventricular ejection fraction <50%) whose diagnosis is documented in the primary health center's electronic health record, and (3) the proportion of participants with confirmed LVSD who receive appropriate treatment, defined as initiation or optimization of guideline-directed medical therapy (GDMT). ACE inhibitors/ARBs and beta-blockers will be the primary treatment indicators, given their recommendations for LVSD even if asymptomatic, as well as their availability in Brazilian public health system. Other recommended therapies, including ARNIs, MRAs, and SGLT2 inhibitors, will also be assessed according to clinical indications and availability. These outcomes will be stratified by the indication for echocardiography (positive AI-ECG screening result or clinical suspicion). |
6 months
|
|
Implementation outcome: Maintenance
Time Frame: 6 months
|
Maintenance will be assessed by comparing the proportion of indicated echocardiograms that are completed during the first three months versus the last three months of participant enrollment. Analyses will be conducted stratified by the indication for echocardiography (positive AI-ECG screening result or clinical suspicion) |
6 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Exploratory: Diagnosis performance of AI-ECG for LVSD only vs. Clinical suspicion only
Time Frame: 6 months
|
Exploratory analyses will be performed for the primary outcome and the secondary outcomes 2, 3, and 4 by comparing participants with positive AI-ECG screening results in the intervention arm with those referred for echocardiography exclusively on the basis of clinical suspicion in the control arm. |
6 months
|
|
Exploratory: Hospitalizations and deaths
Time Frame: 6 months
|
Among participants newly diagnosed with left ventricular systolic dysfunction (LVSD), number and proportion of all-cause hospitalizations and all-cause mortality will be assessed during the six-month follow-up period using standardized questionnaires administered by digital tools and review of administrative data at the municipality's level. Information on hospitalizations will include the occurrence, date, and reason for admission, if available. Hospitalization and mortality outcomes will be compared between the intervention and control groups, accounting for the cluster-randomized study design. |
6 months
|
|
Evaluation of short educational videos by healthcare providers and patients
Time Frame: 6 months
|
Videos will be evaluated by a simplified question if they were useful, with a binary answer, followed by a rank from 1 to 10. |
6 months
|
|
Acceptability of AI-ECG Screening Among Healthcare Professionals
Time Frame: 6 months
|
Healthcare professionals' perceptions of the acceptability of AI-ECG screening will be explored through focus groups. Data will be analyzed using thematic analysis to identify perceived benefits, concerns, and experiences with the screening strategy. |
6 months
|
|
Barriers and Facilitators to AI-ECG Implementation
Time Frame: 6 months
|
Barriers and facilitators to implementing AI-ECG screening in primary healthcare will be explored through focus groups with healthcare professionals and other relevant stakeholders. Data will be analyzed thematically to identify factors influencing implementation. |
6 months
|
|
Budget Impact of AI-ECG Screening
Time Frame: Six-month trial data informing longer-term budget impact projections
|
The budget impact of implementing AI-ECG screening in Brazilian primary healthcare will be estimated by comparing projected healthcare expenditures with and without the screening strategy, including screening, confirmatory testing, treatment, and potential downstream healthcare costs. |
Six-month trial data informing longer-term budget impact projections
|
|
Cost-Effectiveness of AI-ECG Screening
Time Frame: Six-month follow-up, with medium- and long-term projections based on economic modeling.
|
Cost-effectiveness will be assessed by comparing opportunistic AI-ECG screening with usual care in Brazilian primary healthcare. The analysis will include the costs of AI-ECG screening, confirmatory echocardiography, and subsequent clinical management, using study-specific data and Brazilian microcosting studies. Potential long-term reductions in disease progression and associated healthcare costs will be estimated using evidence from published clinical trials. If available, study data on heart failure hospitalizations, emergency visits, and cardiovascular mortality will inform medium- and long-term projections using Markov models or microsimulation. The analysis will estimate the potential cost savings and health benefits associated with earlier LVSD detection and treatment. |
Six-month follow-up, with medium- and long-term projections based on economic modeling.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Luisa C Brant, MD, PhD, Federal University of Minas Gerais
Publications and helpful links
General Publications
- Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812.
- Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999 Sep;89(9):1322-7. doi: 10.2105/ajph.89.9.1322.
- Yao X, Rushlow DR, Inselman JW, McCoy RG, Thacher TD, Behnken EM, Bernard ME, Rosas SL, Akfaly A, Misra A, Molling PE, Krien JS, Foss RM, Barry BA, Siontis KC, Kapa S, Pellikka PA, Lopez-Jimenez F, Attia ZI, Shah ND, Friedman PA, Noseworthy PA. Artificial intelligence-enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial. Nat Med. 2021 May;27(5):815-819. doi: 10.1038/s41591-021-01335-4. Epub 2021 May 6.
- Sangha V, Nargesi AA, Dhingra LS, Khunte A, Mortazavi BJ, Ribeiro AH, Banina E, Adeola O, Garg N, Brandt CA, Miller EJ, Ribeiro ALP, Velazquez EJ, Giatti L, Barreto SM, Foppa M, Yuan N, Ouyang D, Krumholz HM, Khera R. Detection of Left Ventricular Systolic Dysfunction From Electrocardiographic Images. Circulation. 2023 Aug 29;148(9):765-777. doi: 10.1161/CIRCULATIONAHA.122.062646. Epub 2023 Jul 25.
- Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW; ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1.
- Kober L, Adamo M, Ruwald AC, Tomasoni D, Anderson LJ, Andersson C, Brugts JJ, Chioncel O, Donal E, Ferdinandy P, Jhund PS, Leyva F, Lorusso R, Madigan M, Mullens W, Paolillo S, Ryan N, Simpson M, Thiele H, Thune JJ, Van Craenenbroeck EM, Van Laake LW, Verbakel M; ESC Guidelines Advisory Group. 2026 ESC Guidelines for the management of heart failure. Eur Heart J. 2026 Aug 28:ehag100. doi: 10.1093/eurheartj/ehag100. Online ahead of print. No abstract available.
- Elvidge J, Hawksworth C, Avsar TS, Zemplenyi A, Chalkidou A, Petrou S, Petyko Z, Srivastava D, Chandra G, Delaye J, Denniston A, Gomes M, Knies S, Nousios P, Siirtola P, Wang J, Dawoud D; CHEERS-AI Steering Group. Consolidated Health Economic Evaluation Reporting Standards for Interventions That Use Artificial Intelligence (CHEERS-AI). Value Health. 2024 Sep;27(9):1196-1205. doi: 10.1016/j.jval.2024.05.006. Epub 2024 May 23.
- Ghisleni EC, Astolfi VR, Zimmermann L, Lira CNL, Faria do Nascimento E, Etges APBDS, Marcondes-Braga FG, Bacal F, Danzmann LC, Polanczyk CA, Biolo A. Value-based health care in heart failure: Quality of life and cost analysis. Clinics (Sao Paulo). 2023 Oct 28;78:100294. doi: 10.1016/j.clinsp.2023.100294. eCollection 2024.
- Borges E Reges R, Vinhal WC, Pedroso AF, Cardoso CS, Oliveira CR, Brant LCC, Paixao GMM, Sable C, Dhingra LS, Shankar SV, Ribeiro I, Abreu LP, Pires M, Orto FTCD, Sena MD, Souza IS, Dos Santos BAA, de Paula LH, Angelo GR, Gomes PR, Rodrigues SMAF, Lopes RD, Ribeiro ALP, Khera R, Nascimento BR. Identifying Structural Heart Disease and Prioritizing Echocardiography Through Artificial Intelligence-Enabled Tele-ECG: An External Validation of the PROVAR+ Study. Am J Cardiol. 2026 Nov 8:S0002-9149(26)00656-9. doi: 10.1016/j.amjcard.2026.10.022. Online ahead of print.
- Ribeiro ALP, Cardoso CS, Taconeli CA, Di Lorenzo Oliveira C, Gomes PR, Oliveira-da Silva LC, Ferreira AM, Quintino ND, Baldoni NR, Goncalves ACO, Vinhal WC, Cruz DS, Leite SF, de Jesus Santos AC, Silva LA, Cardoso Medeiros FA, Mendes MS, Molina I, Nunes MCP, Schon TB, Ribeiro AH, Sabino EC. Opportunistic Screening for Chagas Disease Using an Artificial Intelligence-Enabled ECG: Prospective Evaluation of Feasibility and Diagnostic Accuracy. Circulation. 2026 Aug 11. doi: 10.1161/CIRCULATIONAHA.125.078949. Online ahead of print.
- Tromp J, Ouwerkerk W, Teng TK, Cleland JGF, Bamadhaj S, Angermann CE, Dahlstrom U, Tay WT, Dickstein K, Ertl G, Hassanein M, Perrone SV, Ghadanfar M, Schweizer A, Obergfell A, Collins SP, Filippatos G, Lam CSP. Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction. Eur Heart J. 2022 Jun 14;43(23):2224-2234. doi: 10.1093/eurheartj/ehac103.
- Walsh MN, Kober L, Sliwa K, Adamo M, Agarwal A, Banerjee A, Bozkurt B, Cikes M, Damasceno A, Desai AS, Michael Felker G, Hogan G, Kinugawa K, Kittleson M, Lam CSP, McDonagh T, Metra M, Mullens W, Ribeiro ALP, Vaughn Y, Vest A; Joint American Heart Association (AHA)/American College of Cardiology (ACC)/European Society of Cardiology (ESC)/World Heart Federation (WHF) Task Force for the Universal Definition of Heart Failure in collaboration with the Heart Failure Society of America (HFSA), the Heart Failure Association (HFA) of the European Society of Cardiology, and the Japanese Heart Failure Society (JHFS). AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026). Eur Heart J. 2026 Aug 24;47(32):4357-4374. doi: 10.1093/eurheartj/ehag500.
- Oliveira GMM, Brant LCC, Polanczyk CA, Malta DC, Biolo A, Nascimento BR, Souza MFM, Lorenzo AR, Fagundes Junior AAP, Schaan BD, Silva CGSE, Castilho FM, Cesena FHY, Soares GP, Xavier Junior GF, Barreto Filho JAS, Passaglia LG, Pinto Filho MM, Machline-Carrion MJ, Bittencourt MS, Pontes Neto OM, Villela PB, Teixeira RA, Stein R, Sampaio RO, Gaziano TA, Perel P, Roth GA, Ribeiro ALP. Cardiovascular Statistics - Brazil 2023. Arq Bras Cardiol. 2024 Feb;121(2):e20240079. doi: 10.36660/abc.20240079. No abstract available. English, Portuguese.
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 93551425.6.0000.0444
- 406938/2024-5 (Other Grant/Funding Number: Conselho Nacional de Desenvolvimento Científico e Tecnológico CNPq)
- U1111-1312-5443 (Registry Identifier: WHO International Clinical Trials Registry Platform (ICTRP))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Time Frame
Data will be available beginning 12 months after publication of the primary study results and will remain available for 5 years.
IPD Sharing Access Criteria
De-identified individual participant data underlying the results reported in the primary publication, including relevant baseline characteristics, ECG findings, echocardiographic results, and study outcomes, will be available upon reasonable request, subject to approval by the study investigators and applicable ethical and data protection requirements.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.